Sue Zhong
Founder
PT
Paramita Therapeutics, Inc.
Paramita Therapeutics is developing targeted therapeutics for cancer and infectious diseases using advanced drug discovery techniques and biomarker identification. The company aims to improve treatment efficacy and patient outcomes by addressing the limitations of current therapies.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$256KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Sang Van
Founder
Jack Bui
Founder
Product
Problem
Current cancer and infectious disease therapies often suffer from limited efficacy and significant side effects due to a lack of precise targeting. This can lead to suboptimal patient outcomes and a reduced quality of life during treatment.
Solution
Paramita Therapeutics is developing targeted therapeutics designed to improve treatment outcomes for cancer and infectious diseases. The company leverages advanced drug discovery techniques in conjunction with biomarker identification to create therapies that selectively target diseased cells while minimizing harm to healthy tissue. By focusing on precision medicine, Paramita aims to enhance treatment efficacy, reduce adverse effects, and ultimately improve the overall patient experience. Their approach seeks to overcome the limitations of traditional therapies by delivering drugs directly to the site of disease, maximizing therapeutic impact.
Target Audience
Paramita Therapeutics targets patients with cancer and infectious diseases, as well as healthcare providers seeking more effective and targeted treatment options.
Features
- Advanced drug discovery platform for identifying novel therapeutic candidates
- Biomarker identification to enable precise targeting of diseased cells
- Development of targeted therapies for cancer and infectious diseases
- Focus on minimizing off-target effects and improving treatment tolerability